CLOs on the Move


 
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.syros.com
  • 620 Memorial Drive Suite 300
    Cambridge, MA USA 02139
  • Phone: 617.744.1340

Executives

Name Title Contact Details
Todd Rosenthal
Assistant General Counsel Profile

Similar Companies

Monticello Drug Companies

Monticello Drug Companies is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UI Magic

UI Magic Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Macrolide Pharmaceuticals

Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.

Summers Laboratories

Summers Laboratories Inc. is a Collegeville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.